Starpharma Financial Statements From 2010 to 2025
| SPHRF Stock | USD 0.25 0.00 0.00% |
Check Starpharma Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Starpharma Holdings' main balance sheet or income statement drivers, such as , as well as many indicators such as . Starpharma financial statements analysis is a perfect complement when working with Starpharma Holdings Valuation or Volatility modules.
Starpharma |
Starpharma Holdings Limited OTC Stock Return On Equity Analysis
Starpharma Holdings' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Starpharma Holdings Return On Equity | -0.29 |
Most of Starpharma Holdings' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Starpharma Holdings Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Starpharma Holdings Limited has a Return On Equity of -0.2919. This is 98.78% lower than that of the Healthcare sector and 99.2% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 5.84% lower than that of the firm.
Starpharma Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Starpharma Holdings's current stock value. Our valuation model uses many indicators to compare Starpharma Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Starpharma Holdings competition to find correlations between indicators driving Starpharma Holdings's intrinsic value. More Info.Starpharma Holdings Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Starpharma Holdings' earnings, one of the primary drivers of an investment's value.About Starpharma Holdings Financial Statements
Starpharma Holdings stakeholders use historical fundamental indicators, such as Starpharma Holdings' revenue or net income, to determine how well the company is positioned to perform in the future. Although Starpharma Holdings investors may analyze each financial statement separately, they are all interrelated. For example, changes in Starpharma Holdings' assets and liabilities are reflected in the revenues and expenses on Starpharma Holdings' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Starpharma Holdings Limited. Please read more on our technical analysis and fundamental analysis pages.
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company was founded in 1996 and is headquartered in Abbotsford, Australia. Starpharma Holdings operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 50 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Starpharma OTC Stock
Starpharma Holdings financial ratios help investors to determine whether Starpharma OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Starpharma with respect to the benefits of owning Starpharma Holdings security.